MarketPulse

HyBryte™

4 articles
BenzingaBenzinga··Soligenix, Inc.

Soligenix's HyBryte Outperforms Valchlor in Cutaneous Lymphoma Study

Soligenix's HyBryte demonstrated superior efficacy versus Valchlor in treating cutaneous T-cell lymphoma, with 60% versus 20% success rates at 12 weeks, backed by $2.6M FDA grant.
SNGXFDA approvalclinical trial
BenzingaBenzinga··Soligenix, Inc.

Soligenix Burns Through Cash as Rare Disease Pipeline Awaits Make-or-Break 2026 Trials

Soligenix reported zero 2025 revenue and $11.1M net loss. Company has $7.9M cash, seeking partnerships to fund operations through Q4 2026 pivotal trials.
SNGXPhase 3 clinical trialbiopharmaceutical
BenzingaBenzinga··Soligenix, Inc.

Soligenix's HyBryte Shows Promise Against Cutaneous Lymphoma at 2026 Workshop

Soligenix's HyBryte™ cutaneous lymphoma therapy shows positive results ahead of 2026 presentation, with FDA awarding $2.6M development grant.
SNGXPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Ibn

Soligenix Reports Promising 48% Response Rate in HyBryte Phase 3 Study

Soligenix's HyBryte study shows 48% response rate, nearly double the 25% threshold, with interim results expected this quarter.
SNGXPhase 3 clinical trialbiotech